Overview
To protect vulnerable people from serious viral threats, we are taking a unique, platform-based approach that is grounded in a commitment to serial innovation and designed to anticipate and quickly respond to viral evolution.
With our integrated discovery platform, we are continuously identifying and engineering new monoclonal antibody (mAb) candidates that can be leveraged to keep pace with viral evolution.
Viral Surveillance & Predictive Modeling
We monitor viral evolution continuously and map common mutational escape routes with the aim to predict potential future variants of concern.
Antibody Discovery
We utilize deep B-cell mining capabilities to isolate broadly neutralizing antibodies that target rare viral epitopes (portions of the virus) that are not under strong immune pressure, thereby increasing the probability of sustained utility.
Antibody Engineering
We leverage industry-leading antibody engineering capabilities to improve the potency, breadth, biophysical properties, and developability of the candidates discovered through B-cell mining. For example, through an iterative process known as affinity maturation, we can engineer candidates to have high activity against specific viral variants that we identify as potential future variants of concern.
STREAM OF mAb CANDIDATES
With our platform, we are generating a stream of mAb candidates designed to perpetually protect vulnerable populations from serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Our robust discovery pipeline reflects our strategy to predict and respond to variants before they become variants of concern.
Latest publications
